WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

10 € finde ich schon sportlich, aber bekanntlich ist ja nichts unmöglich 🙃

Wird wohl nichts mit den 10 € 😂 aber lass das Körbchen mal dort stehen. Selten solch eine Gegenbewegung gesehen. Chapeau!

JPM: Focus on High-Quality Pharmas Post-correction, Incl. WUXI BIO, WUXI APPTEC http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1115772/hk-stock-news

Bei 10,00 Euro ist mein Körbchen aufgestellt. Mal gucken ob noch ein paar eingesammelt werden

Ja, ist momentan nicht so einfach. Heute gibt es eine gewisse Gegenbewegung, aber ob sie bei der Politik und Marktlage die Tage/ Wochen anhalten wird, bleibt natürlich fraglich.

Hier geht es jetzt auch richtig in den Keller.

Diese Regierung sorgt noch dafür, dass ich graue Haare bekomme...🤦‍♂️

M Stanley's Ratings, TPs on CN Pharma, Medical-related Shrs; 4 Top-pick List (Table) http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1115314/hk-stock-news ... Morgan Stanley's four pharma top-picks are as follows: ... WUXI BIO (02269 HK) | Overweight｜164

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility https://finance.yahoo.com/news/wuxi-biologics-received-commercial-manufacturing-100000327.html • First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system • Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" ...

Hong Kong stocks move | Pharmaceutical stocks fell more than 4% in early trading, WuXi Biologics (02269) fell more than 8% at one point https://finance.sina.cn/hkstock/ggyw/2021-07-26/detail-ikqciyzk7668060.d.html?from=wap

http://www.aastocks.com/en/stocks/news/aafn-con/rum.210721_103236/latest-news

WuXi Biologics to cash in $10b https://www.thestandard.com.hk/section-news/section/2/232309/WuXi-Biologics-to-cash-in-$10b WuXi Biologics, the major shareholder of Wuxi Biologics Cayman (2269) plans to offload 78 million shares to cash in HK$10 billion. It is seeking to raise up to US$1.3 billion (HK$10.07 billion) by placing the shares at a range between HK$128 and HK$130. This represents a discount of between 5.8 percent and 7.3 percent against yesterday's closing price of HK$138.69 million. Morgan Stanley is the sole placement agent. ...

Ein sehr ausführlicher Artikel zur WuXi Bio und lässt sich auch ohne die App öffnen: China Securities: Maintain WuXi Biologics (02269) "overweight" rating target price of 163.48 Hong Kong dollars https://wap.eastmoney.com/a/202107162000870883.html

Etwas umfangreicher und für den Übersetzer: https://hk.on.cc/hk/bkn/cnt/finance/20210714/mobile/bkn-20210714073141592-0714_00842_001.html

WUXI BIO Projects 1H NP to Surge by Over 1.35x YoY http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1112315/recommend-news WUXI BIO issued a positive profit alert. It is expected that the net profit for the six months ended June 30, 2021 will increase more than 135% compared with that for the corresponding period of last year. Such increase was primarily attributable to: the Group’s acceleration to undertake, promptly execute and generate revenue from existing and new COVID-19 projects to support and enable the Group’s global clients in the first half of 2021 in combatting against COVID-19; leading technology platform, best-in-industry timeline and excellent execution track record contributing to significantly higher revenue and market share of new integrated projects; and so on.

https://hk.investing.com/news/stock-market-news/article-176503 ... WuXi Biologics (2269.HK): Accelerate upward, target 175 Hong Kong dollars Source: GAIN Capital, TradingView WuXi Biologics (2269.HK), a Chinese biopharmaceutical service provider, has risen more than 15% so far in June and hit a record high. The investment bank Macquarie has given the company an "Outperform" rating, and expects that future growth will continue to be strong due to the support of the new coronavirus vaccine and antibody-drug complex project. Morgan Stanley also expects the global biological product outsourcing services to develop prosperously, and it is expected that WuXi Biologics will maintain its leading position in the Chinese market and give it an "overweight" rating. From a technical point of view, as shown on the daily chart, WuXi Biologics stock price has accelerated recently, breaking the rising channel pulled from March, and the technical landscape is extremely bullish. Currently, it is trading above the 20- and 50-day moving averages, and the relative strength indicator has not shown a clear bearish divergence. The stock price has not seen fatigue and should rise to the upside target of HK$160.00 and HK$175.00. The main support (stop loss) for the bullish trend has been raised to HK$118.00.